Skip to Content

'
Ana Aparicio, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3512
Phone: (713) 563-6969
Fax: (713) 745-1625

Education & Training

Degree-Granting Education

1995 Universidad Autonoma de Madrid, Madrid, Spain, MD, Medicine

Postgraduate Training

7/2000-7/2003 Medical Oncology Fellowship, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Keck School of Medicine, Los Angeles, CA
6/1997-6/2000 Clinical Internship, Internal Medicine, West Los Angeles VA Medical Center, UCLA School of Medicine,, Los Angeles, CA
4/1996-4/1997 Clinical Residency, Medical Oncology, Hospital Universitario Doce de Octubre, Universidad Complutense de Madrid,, Madrid, Spain

Board Certifications

2003 Medical Oncology
2003 Hematology
2000 Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Medicine, Division of Medical Oncology, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA, 2004-2006
Clinical Instructor,, Department of Medicine, Division Medical Oncology, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA, 2003-2004

Other Appointments/Responsibilities

Regular Faculty Member, Member of The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 2007-2012

Honors and Awards

2002 Chief Fellow, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA
2002 Outstanding Fellow of the Year, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA
2000 Solomon Scholars Award for Outstanding Research During Residency, UCLA School of Medicine
1998 Solomon Scholars Award for Outstanding Research During Residency, UCLA School of Medicine
1992 Erasmus Scholarship, Granted by the European Community for Academic Excellence

Selected Publications

Peer-Reviewed Original Research Articles
1. Aparicio AM, Harzstark A, Corn PG, Wen S, Araujo J, Tu SM, Pagliaro L, Kim J, Millikan RE, Ryan CJ, Tannir NM, Zurita A, Mathew P, Arap W, Troncoso P, Thall P, Logothetis CJ. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clin Cancer Res. e-Pub 5/6/2013. PMID: 23649003.
2. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma. Eur Urol 62(6):1013-9, 12/2012. e-Pub 6/27/2012. PMID: 22771265.
3. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol 180(3):895-903, 3/2012. e-Pub 1/2012. PMID: 22245216.
4. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling lethal prostate cancer variant with small cell carcinoma features. Clin Cancer Res 18(3):666-77, 2/2012. e-Pub 12/2011. PMID: 22156612.
5. Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, Aparicio AM, Ribas A, Sondak VK. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One 7(11):e48787, 2012. e-Pub 11/2012. PMCID: PMC3511501.
6. Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Xiao L, Boehm KA, Asmar L, Fleming MT, Galsky MD, Berry WR, Von Hoff DD. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer. Urol Oncol 29(6):682-9, Nov-Dec, 11/2011. e-Pub 12/2009. PMID: 19959380.
7. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: Morphological, immunohistochemical and gene expression profiles. Prostate 71(8):846-56, 6/1/2011. e-Pub 11/17/2010. PMID: 21456067.
8. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol 34(1):27-31, 2/2011. e-Pub 2/2010. PMID: 20142723.
9. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 42(1):11-7, 1/2011. e-Pub 10/30/2010. PMID: 21040948.
10. Albany C, Alva AS, Aparicio AM, Singal R, Yellapragada S, Sonpavde G, Hahn NM. Epigenetics in prostate cancer. Prostate Cancer 2011:580318, 2011. e-Pub 11/2011. PMCID: PMC3236424.
11. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront randomized phase II trial of sorafenib versus sorafenib and low-dose interferon alpha in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116(1):57-65, 1/1/2010. PMID: 19862815.
12. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 9/1/2009. e-Pub 7/27/2009. PMID: 19636008.
13. Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL. Ductal adenocarcinoma of the prostate:clinical features and implications after local therapy. Cancer 115(13):2872-80, 7/1/2009. PMID: 19402048.
14. Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, Jones P, Yang A, Issa JP. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics 4(3):176-84, 4/1/2009. e-Pub 4/6/2009. PMCID: PMC2848123.
15. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics 4(2):48, 2009. e-Pub 8/4/2009. PMCID: PMC2731785.
16. Luu TH, Morgan RJ, Leong L, Lim D, McNarmara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara DR, Somlo G. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California Cancer Consortium study. Clin Cancer Res 14(21):7138-42, 11/2008. PMID: 18272030.
17. Egger G, Aparicio AM, Escobar SG, Jones PA. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res 67(1):346-53, 1/1/2007. PMID: 17210717.
18. Aparicio A, Eads C, Leong L, Laird PW, Newman N, Weber JS. Phase I Trial of continuous infusion 5-Aza-2'-deoxyctidine (DAC). Cancer Chemother Pharmacol 51(3):231-39, 3/2003. PMID: 12655442.
19. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12(2):220-29, 2/1998. PMID: 9519785.
20. Tannir N, Plimack E, Ng, C, Pheroze T, Neby B, Lianchun X, Smith L, Zita L, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood C, Jonasch E. Tumor heterogeneity is reflected in the response of advance non-clear cell renal cell carcinomato sunitinib therapy:. J Clin Oncol. Submitted.

Invited Articles
1. Aparicio A, Den RB, Knudsen KE. Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat Rev Urol 8(10):562-8, 10/2011. e-Pub 8/2011. PMID: 21811228.
2. Alva AS, Hahn NM, Aparicio AM, Singal R, Yellapragada S, Sonpavde G. Hypomethylating agents for urologic cancers. Future Oncol 7(3)(3):447-63, 3/2011. PMID: 21417907.
3. Aparicio A. The potential of histone deacetylase inhibitors in lung cancer. Clin Lung Cancer 7(5)(5):309-12, 3/2006. PMID: 16640801.
4. Aparicio AM, Elkhouiery AB, Quinn DI. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Urol Clin North Am 32(2):217-30, 5/2005. PMID: 15862619.
5. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990):457-63, 5/2004. PMID: 15164071.
6. Aparicio A, Chamberlain MC. Neoplastic meningitis. Curr Neurol Neurosci Rep 2(3):225-35, 5/2002. PMID: 11937001.
7. Aparicio A, Weber JS. Review of the clinical experience with 5-Azacytidine and 5-Aza-2'-deoxycytidine in solid tumors. Curr Opin Investig Drugs 3(4):627-33, 4/2002. PMID: 12090735.
8. Weber JS, Aparicio A. Novel immunologic approaches to the management of malignant melanoma. Curr Opin Oncol 13(2):124-28, 3/2001. PMID: 11224710.

Editorials
1. Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: Power of examining extremes. Cancer Discov 1(6):466-8, 11/2011. PMID: 22586648.
Other Articles
1. Aparicio AM. Prostate Cancer: Clinical practitioner perspective. Endocrine News, 9/2011.
2. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone Nora, Troncoso P, Liang S, Logothetis C, Maity S, Aparicio A. Novel Small-Cell Prostate Carcinoma Models Reveal Marked Upregulation of UBE2C in the Absence of Androgen Receptor, Retinoblastoma, and Cyclin D1 Expression. Submitted. NIHMSID: NIHMS111561.

Abstracts
1. Aparicio A, Maity S, Wang X, Hoang AG, Efstathiou E, Troncoso P, Logothetis CJ,. A molecular Characterization of the anaplastic prostate carcinomas. AACR Annual Meeting (#7587), 4/2013.
2. Aparicio A, Gallichotte E, Cheng H, Yoo SY, Maity S, Logothetis CJ, Tewari M,. Circulating micro-RNAs can detect adaptive response to therapy and aggressive subset of prostate cancer. AACR Annual Meeting (#5692), 4/2013.
3. Kleb BN, Estecio M, Wu G, Lu JF, Logothetis CJ, Maity S, Aparicio A. Mechanism of androgen receptor (AR) silencing in small cell prostate carcinoma. AACR Annual Meeting (#6786), 4/2013.
4. Aparicio A, Sun, J, Ng Tang D, Arap W, Araujo J, Corn P, Tannir N, Wang X, Radtke A, Sharma P,. A phase II study of ipilumimab plus adnrogen deprivation therapy in castration-sensitive prostate carcinoma. AACR Annual Meeting (#5368), 4/2012.
5. Kleb B, Estecio M, Zhang J, Tzelepi V, Chung, W, Maity S, Logothetis C, Troncoso P, Navone N, Jelinek J, Liang S, Issa J, Aparicio A. The DNA methylome of castration-resistant prostate cancer. AACR Annual Meeting (#991), 4/2012.
6. Aparicio A, Harzstark L, Lin E, Corn P, Araujo J, Tu S, Pagliaro L, Millikan R, Arap W, Kim J, Ryan C, Zurita A, Tannir N, Lin A, Small J, Mathew P, Jones D, Troncoso P, Thall P, Logothetis C. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol 29 (#4666), 6/2011.
7. Tzeelpi V, Maity S, Zhang J, Liang S, Lu JF, Anh H, Kleb B, Efstathiou E, Navone N, Troncoso P, Logothetis C, Aparicio A. Molecular profiling of prostate cancer xenografts and human specimens reveals overexpression of UBE2C/UBCH10 and activation of aurora kinases in poorly differentiated neuroendocrine carcinoma of the prostate. Cancer Research 71(8):10.1158/1538-7445.AM2011-36 (#36), 4/2011.
8. Efstathiou E, Tu S, Aparicio A, Hoang A, Troncoso P, Smith L, Chieffo N, Molina A, Logothetis C,. Use of "intracrine androgen signaling signature" to predict benefit from abiraterrone acetate(AA) in patients with castrate-resistant prostate cancer (CRPC). J Clin Oncol 28(15s) (#4547), 2010.
9. Jonasch E, Wood G, Matin S, Tamboli K, Do L, Pagliaro C, Aparicio AM, Araujo JC, Tannir NM. Presurgical bevacizumab in patients with metastatic clear cell renal cell carcinoma: A phase II study. J Clin Oncol 26(15S):275s (#5104), 5/2008.
10. Aparicio AM, Lin AM, Araujo JC, Logothetis CJ, Kim J, Pagliaro LC, Tu S, Guo C, Jones D, Thall P, Mathew P. Use of clinical features to select a chemotherapy-responsive variant of aggressive prostate cancer (PC). J Clin Oncol 26(15S):271s (#16000), 5/2008.
11. Ramalingam S, Parise RA, Egorin MJ, Argiris A, Stoller R, Beattie l, Aparicio A, Newman EM, Zwiebel J, Belani CP. Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI # 6922). J Clin Oncol 24(18S) (#2077), 2006.
12. Dorff TB, Rupani R, Wei DT, Groshen S, Pinski J, Raghavan D, Quinn D, A. POMB-ACE therapy for patients with international germ cell cancer collaborative group (IGCCCG) poor risk germ cell tumors (GCT): The USC experience. J Clin Oncol 24(18S) (#4591), 2006.
13. Egger G, Aparicio A, Escobar S, Jones PA. Effects of combinatiorial treatment of T24 cells with 5-aza-2' deoxycytidine and 4-phenylbutyric acid. AACR 96th Annual Meeting Proceedings Vol 46 (#1819), 2005.

Book Chapters
1. Logothetis CJ, Troncoso P, Kim J, Davis JW, Kuban DA, Mathew P, Aparicio A. Neoplasm of the Prostate. In: Cancer Medicine, 8th. People Medical Publishing House-USA: Shelton, CONN, 1228-1254, 2010.
2. Aparicio A, Sharma P, Millikan RE. Experimental systemic therapy of metastatic urothelial cancer. In: UpToDate, Basow, DS(Ed), UpToDate, Waltham, MA, 2009.

Grant & Contract Support

Title: Characterization of the Anaplastic Prostate Carcinomas
Funding Source: NIH-Spore-CDA
Role: Principal Investigator
Duration: 1/7/2012 - 8/31/2014
 
Title: Characterizing the Anaplastic Prostate Carcinomas
Funding Source: Texas Foundation Business Professional Women (TFBPW)
Role: Award Recipient
Duration: 2/2010 - present
 
Title: Biomarkers of Epigenetic Therapy
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2010
 
Title: Biologic Markers of Activity in Epigenetic Therapy in a Phase I Trial of Low Doses of Decitabine with Oral Sodium Phenylbutyrate in Patients with Solid Tumors
Funding Source: Wright Foundation
Role: Principal Investigator
Duration: 7/1/2004 - 6/1/2006
 
Title: Pilot Study of Biomaker of Epigenetic Therapy in Peripheral Blood and Oral Mucosa Cells, Seed Grant Award
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: - 11/19/2004

Last updated: 5/15/2013